Form 4: Royalty Pharma EVP Marshall Urist Sells Shares

EVP of Research & Investments Marshall Urist sold 13,684 Class A Ordinary Shares of Royalty Pharma plc via a 10b5-1 trading plan.

Summary

• Marshall Urist, EVP of Research & Investments at Royalty Pharma, sold 13,684 Class A Ordinary Shares on May 20, 2026.
• The shares were sold at a weighted average price of $52.7505 per share, with individual transaction prices ranging from $52.62 to $52.96.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2026.
• Following the transaction, Urist retains direct ownership of 18,197 shares and indirect ownership of 19,020 shares held in an IRA.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-established 10b5-1 plan, which is standard practice for executive liquidity.

Positives

• The transaction was pre-planned under a Rule 10b5-1 plan, indicating the sale was not based on non-public information or sudden market sentiment.

Negatives

• The sale represents a reduction in the direct equity stake held by a key executive involved in research and investments.

Risks

• Executive stock sales can sometimes be perceived by the market as a lack of confidence in future share price appreciation, though 10b5-1 plans are standard for liquidity management.

Future Outlook

No specific forward-looking guidance regarding company performance was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a common practice for executives to diversify personal wealth and is generally viewed as a neutral event rather than a signal of operational distress.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for corporate insiders to sell shares while maintaining compliance with SEC regulations regarding insider trading.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was pre-planned and represents a small portion of the executive's total potential holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Royalty Pharma, RPRX, Insider Trading, Form 4, Marshall Urist, Equity Sale